Pericyte-Sparing CD19 Therapy for Neurotoxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CD19-targeted therapies for B-cell lymphomas and leukemias often cause significant neurotoxicity due to damage to neurovascular pericytes and vascular smooth muscle cells, leading to disruption of the blood-brain barrier, with the mechanism of neurotoxicity not fully understood and effective methods to reduce this side effect being urgently needed.
Innovation Solution
Development of protective agents that bind to CD19 on neurovascular pericytes and vascular smooth muscle cells, down-regulate CD19 expression, or use bispecific binding agents activating immune checkpoints to reduce the impact of CD19-targeted therapies, thereby minimizing damage to these cells and preserving the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD19 therapy is administered to treat B-cell lymphomas and leukemias, then therapeutic efficacy is improved, but neurotoxicity increases due to damage to neurovascular pericytes and vascular smooth muscle cells
Solution Approach 1:
The patent uses CD19-binding agents as intermediaries that selectively bind to CD19 on B-cell malignancies while sparing neurovascular pericytes and vascular smooth muscle cells. This mediator approach allows the therapy to target cancer cells without directly damaging healthy neurovascular cells, thereby maintaining therapeutic efficacy while reducing neurotoxicity
Solution Approach 2:
The patent applies local quality by creating spatial and functional differentiation in CD19 expression targeting. By recognizing that CD19 is expressed differently on B-cell malignancies versus neurovascular cells, the therapy can be localized to preferentially affect cancer cells while preserving healthy tissue, thus resolving the contradiction between efficacy and neurotoxicity
2Productivity
If CD19-targeted therapy is used to eliminate B-cell cancers, then disease remission is achieved, but blood-brain barrier disruption occurs due to pericyte damage
Solution Approach 1:
The patent employs protective agents as intermediaries that specifically protect neurovascular pericytes from CD19-targeted therapy damage. These intermediary substances allow the main therapy to continue eliminating B-cell cancers while the protective intermediaries maintain blood-brain barrier integrity by shielding pericytes from cytotoxic effects
Solution Approach 2:
The patent applies beforehand cushioning by administering protective agents prior to or during CD19-targeted therapy to preemptively shield neurovascular pericytes. This prior protection prevents blood-brain barrier disruption before it can occur, allowing aggressive cancer treatment while maintaining barrier integrity
Data Source
AI summary
Methods and systems to reduce neurotoxicity associated with the treatment of CD19+ B-cell hyperproliferative disorders are disclosed. Neurotoxicity is reduced by the use of agents that protect CD19+ neurovascular pericytes and/or CD19+ vSMCs from attack by CD19-targeted therapy, and by modification of CD19-targeted therapy to avoid CD19+ pericytes and/or CD19+ vSMCs.